[Form 4] Health Catalyst, Inc Insider Trading Activity
Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 4,578 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax-withholding obligations tied to the vesting of restricted stock units. The filing lists 375,087 shares beneficially owned by Freeman after the transaction. The disclosure clarifies this was a sell-to-cover transaction required by the issuer's equity plan and was not a voluntary sale by the reporting person.
Kevin Lee Freeman, Chief Commercial Officer di Health Catalyst, Inc. (HCAT), ha comunicato una vendita non discrezionale di 4.578 azioni ordinarie il 02/09/2025 al prezzo di $3,3627 per azione per assolvere agli obblighi di ritenuta fiscale connessi alla maturazione di restricted stock unit. La documentazione indica che dopo la transazione Freeman detiene utilmente 375.087 azioni. La divulgazione specifica che si è trattato di un’operazione di sell-to-cover prevista dal piano azionario dell’emittente e non di una vendita volontaria della persona che effettua la segnalazione.
Kevin Lee Freeman, Chief Commercial Officer de Health Catalyst, Inc. (HCAT), informó una venta no discrecional de 4.578 acciones ordinarias el 02/09/2025 a $3,3627 por acción para cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas. El expediente indica que tras la operación Freeman posee beneficiariamente 375.087 acciones. La comunicación aclara que fue una transacción de sell-to-cover exigida por el plan de acciones del emisor y no una venta voluntaria del informante.
Kevin Lee Freeman은(는) Health Catalyst, Inc.(HCAT)의 최고 상업 책임자로서 제한주식단위(RSU)의 취득에 따른 세금 원천징수 의무를 충족하기 위해 2025년 9월 2일에 보통주 4,578주를 주당 $3.3627에 비임의적(non-discretionary)으로 매도했다고 보고했습니다. 제출서류에는 거래 후 Freeman이 실질적으로 보유한 주식이 375,087주로 기재되어 있습니다. 공시는 해당 거래가 발행사의 주식 보상 플랜에 따라 요구된 sell-to-cover 거래였으며 보고인의 자발적 매도가 아니었다고 명시합니다.
Kevin Lee Freeman, Chief Commercial Officer de Health Catalyst, Inc. (HCAT), a déclaré une cession non discrétionnaire de 4 578 actions ordinaires le 02/09/2025 au prix de 3,3627 $ par action afin de satisfaire aux obligations de retenue à la source liées à la levée de restricted stock units. Le dossier indique qu'après la transaction Freeman détient bénéficiairement 375 087 actions. La divulgation précise qu'il s'agissait d'une opération de sell-to-cover requise par le plan d'actions de l'émetteur et non d'une vente volontaire de la personne déclarante.
Kevin Lee Freeman, Chief Commercial Officer von Health Catalyst, Inc. (HCAT), meldete am 02.09.2025 einen nicht diskretionären Verkauf von 4.578 Stammaktien zu $3,3627 je Aktie, um steuerliche Abzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock Units zu erfüllen. Die Einreichung gibt an, dass Freeman nach der Transaktion wirtschaftlich 375.087 Aktien besitzt. Die Offenlegung stellt klar, dass es sich um eine vom Emittentenplan vorgeschriebene sell-to-cover-Transaktion handelte und nicht um einen freiwilligen Verkauf der meldenden Person.
- None.
- None.
Insights
TL;DR: Routine sell-to-cover for RSU taxes; maintains substantial ownership, no indication of voluntary disposition.
The Form 4 documents a compliance-driven sale to satisfy tax withholding from RSU vesting rather than an active, discretionary trade. From a governance perspective, such transactions are common and typically viewed as neutral on insider signaling because the holder retains a large stake—reported at 375,087 shares—after the cover sale. The filing is correctly documented with transaction code and explanatory remark, indicating appropriate disclosure practice.
TL;DR: Small compulsory disposition relative to total holdings; no material change to insider ownership profile.
The reported sale of 4,578 shares at $3.3627 per share represents a modest reduction in holdings and is expressly tied to tax withholding on vested RSUs. Because the transaction is non-discretionary and the reporting person continues to hold 375,087 shares, this Form 4 does not materially alter insider alignment with shareholders nor signal a change in confidence in company prospects based on the disclosed facts alone.
Kevin Lee Freeman, Chief Commercial Officer di Health Catalyst, Inc. (HCAT), ha comunicato una vendita non discrezionale di 4.578 azioni ordinarie il 02/09/2025 al prezzo di $3,3627 per azione per assolvere agli obblighi di ritenuta fiscale connessi alla maturazione di restricted stock unit. La documentazione indica che dopo la transazione Freeman detiene utilmente 375.087 azioni. La divulgazione specifica che si è trattato di un’operazione di sell-to-cover prevista dal piano azionario dell’emittente e non di una vendita volontaria della persona che effettua la segnalazione.
Kevin Lee Freeman, Chief Commercial Officer de Health Catalyst, Inc. (HCAT), informó una venta no discrecional de 4.578 acciones ordinarias el 02/09/2025 a $3,3627 por acción para cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas. El expediente indica que tras la operación Freeman posee beneficiariamente 375.087 acciones. La comunicación aclara que fue una transacción de sell-to-cover exigida por el plan de acciones del emisor y no una venta voluntaria del informante.
Kevin Lee Freeman은(는) Health Catalyst, Inc.(HCAT)의 최고 상업 책임자로서 제한주식단위(RSU)의 취득에 따른 세금 원천징수 의무를 충족하기 위해 2025년 9월 2일에 보통주 4,578주를 주당 $3.3627에 비임의적(non-discretionary)으로 매도했다고 보고했습니다. 제출서류에는 거래 후 Freeman이 실질적으로 보유한 주식이 375,087주로 기재되어 있습니다. 공시는 해당 거래가 발행사의 주식 보상 플랜에 따라 요구된 sell-to-cover 거래였으며 보고인의 자발적 매도가 아니었다고 명시합니다.
Kevin Lee Freeman, Chief Commercial Officer de Health Catalyst, Inc. (HCAT), a déclaré une cession non discrétionnaire de 4 578 actions ordinaires le 02/09/2025 au prix de 3,3627 $ par action afin de satisfaire aux obligations de retenue à la source liées à la levée de restricted stock units. Le dossier indique qu'après la transaction Freeman détient bénéficiairement 375 087 actions. La divulgation précise qu'il s'agissait d'une opération de sell-to-cover requise par le plan d'actions de l'émetteur et non d'une vente volontaire de la personne déclarante.
Kevin Lee Freeman, Chief Commercial Officer von Health Catalyst, Inc. (HCAT), meldete am 02.09.2025 einen nicht diskretionären Verkauf von 4.578 Stammaktien zu $3,3627 je Aktie, um steuerliche Abzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock Units zu erfüllen. Die Einreichung gibt an, dass Freeman nach der Transaktion wirtschaftlich 375.087 Aktien besitzt. Die Offenlegung stellt klar, dass es sich um eine vom Emittentenplan vorgeschriebene sell-to-cover-Transaktion handelte und nicht um einen freiwilligen Verkauf der meldenden Person.
FAQ
What did Kevin Lee Freeman report on Form 4 for HCAT?
Why were the shares sold according to the filing?
How many HCAT shares does the reporting person own after the transaction?
Does the Form 4 indicate a discretionary insider sale?
